Tuesday, March 15, 2016
Bio & Pharmaceutical Patent Forum (Shanghai)
1:30 p.m. Registration
2:00-5:30 p.m. Seminar
Cocktails and Hors D’oeuvre Reception to Follow
We invite you to join our distinguished group of Bio & Pharmaceutical Patent Forum and litigation experts for this informative and interactive discussion, which will position you to preserve and enhance your company’s ability to protect and commercialize intellectual property in China’s rapidly changing IP environment.
Our speakers will discuss:
Creating Extra Value From Your Discoveries – Obtaining IP Rights for Salts, Isotopes and Polymorphs
We will review the advantages and challenges of patenting salt forms, isotopic derivatives and polymorphic forms of compounds. In addition, we will review examples of how these types of APIs can be used to create value by extending the patent monopoly or creating exclusivity via the FDA’s Orange Book. Presented by Alexander R. Trimble, Ph.D.
What Biotechnology Can You Patent? – What’s in, What’s out, and What’s Your Best Bet for Protecting Your Innovations
The recent examination guidance on patentable subject matter issued by the U.S. Patent & Trademark Office (USPTO) presents a formidable challenge to the biotechnology industry for obtaining patent protection on nature-based products and diagnostic methods. This presentation will provide an overview of recent U.S. Supreme Court jurisprudence on patentable subject matter and the USPTO examination guidance, as well as claim drafting considerations. Both hypothetical and real-world examples of patent-eligible claims will be presented and discussed. Presented by Joe C. Hao, Ph.D.
Asserting Your Rights/Defending Your Rights – Overview of Litigation and Life Cycle Planning for Drugs and Biologics
A coherent overview of Hatch-Waxman and biosimilars provisions, including what to expect in Hatch-Waxman litigation or the “patent dance” provided for in the Biologics Price Competition and Innovations Act of 2009 (BPCIA). The presentation will include discussion of paragraph IV certifications and notice letters, hot button issues in litigation, and practical information to consider when anticipating future enforcement of pharmaceutical and biotechnology patents. Presented by Alyson L. Wooten, Pharm.D.
Simultaneous translation services will be provided.
Who Should Attend?
Pharmaceutical and biotechnology In-house counsel, IP managers and staff, business managers, patent agents, patent engineers and others tasked with understanding and managing patent portfolios and strategy will benefit from this timely analysis of recent and upcoming changes in U.S. law. Our seminars – and question/answer time – will be followed by a cocktail reception for our clients, special guests and colleagues.
For more information, please contact Holly Chen at firstname.lastname@example.org.
Tuesday, March 15, 2016
The Evergreen Laurel Hotel
Laurel Room 1, No.1136 Zuchongzhi Road, Shanghai Pudong Software Park
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.